Treating Myelodysplastic Syndromes Transformation to Acute Myeloid Leukemia
Recorded on: September 19, 2024
1.0 CME Credit for physicians available until: October 27, 2025
1.0 CE Contact hour for nurses available until: October 27, 2025
1.0 CE Contact hour for nurse practitioners available until: December 31, 2025
Format: Non-interactive recorded webinar
Target Audience
This activity is intended for hematologist/oncologists, oncology nurses, and other healthcare professionals involved in the care of patients with hematologic malignancies.
Educational Objectives
After completing this activity, the participant should be better able to:
- Provide an overview of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
- Explain the progression from MDS to AML, including the factors that influence the transformation and the clinical implications
- Discuss the diagnostic criteria for distinguishing MDS from AML
- Describe the treatment options and management strategies for both MDS and AML, including emerging therapies
- Review resources and education to support patients, caregivers, and healthcare professionals
Faculty
Aref Al-Kali, MD
Professor of Medicine
MDS Clinic Director
Acute Myeloid Group Chair
Section Head
Division of Hematology
Mayo Clinic
Rochester, MN
Jennifer Andres, MSN, RN, FNP-C
Outpatient Hematology Nurse Practitioner
Mayo Clinic
Phoenix, AZ
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24116976. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
Providers
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.
Supporters
There is no commercial support associated with this CE activity.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.